GHRP-2 (Pralmorelin): Potent GH Release, Thin Outcome Data

At a Glance

GHRP-2 is the most pharmacologically respectable member of the old growth hormone-releasing peptide family. It has a human file that most research peptides never get: dose-response data, a validated diagnostic protocol, a 30-day continuous infusion study in older adults, and a regulatory approval in Japan for one narrow diagnostic use.

The honest verdict is that we know precisely what GHRP-2 does to hormones and almost nothing about what it does to people. Every published human study measured a hormone, an appetite score or a diagnostic cut-off. None measured lean mass at six months, injury recovery, strength, or a hard clinical endpoint. The gap between “this reliably raises GH and IGF-1” and “this improves something that matters” is where the entire off-label market sits.

That does not make it uninteresting. A compound with a reproducible pharmacodynamic effect, decades of exposure in research settings and a known side-effect profile is a better starting point than most peptides on the grey market. It simply has to be described accurately.

How it works

The pituitary releases growth hormone under two opposing hypothalamic signals: GHRH stimulates, somatostatin restrains. In the 1980s Cyril Bowers’ group found that small synthetic peptides released GH through neither pathway. The first well-characterised one was a hexapeptide that specifically released GH in rats, monkeys, lambs and calves without moving LH, FSH, TSH or prolactin in the same assays (Bowers 1984).

That receptor was identified years later as GHS-R1a, and its natural ligand turned out to be ghrelin. GHRP-2 is a second-generation analogue of the original hexapeptide, modified for potency and stability. Three consequences follow from the receptor it uses:

• It amplifies pulses rather than flattening them. GHS-R1a activation works partly by reducing somatostatin tone and partly through a different intracellular pathway from GHRH. The result is a larger GH pulse that still respects feedback, which is why a GHRP combined with GHRH produces more GH than either alone (Bowers 1990).
• It carries ghrelin’s other jobs with it. The same receptor drives appetite and gastric motility, so hunger is part of the pharmacology, not a contaminant.
• It is not fully selective at the pituitary. At GH-releasing doses, GHRP-2 also raises prolactin, ACTH and cortisol, modestly but measurably (Arvat 1997). That is the main pharmacological difference from ipamorelin.

What the evidence shows

Human data

Acute GH release. The parent hexapeptide raised peak GH from 1.2 mcg/L on placebo to 68.7 mcg/L at 1 mcg/kg intravenously in 18 normal men, with no adverse clinical effects and clear synergy when combined with GHRH (Bowers 1990). For GHRP-2 specifically, a study in young and elderly adults confirmed potent GH release at 1-2 mcg/kg intravenously, with small rises in prolactin, ACTH and cortisol that were smaller than those produced by CRH (Arvat 1997).

Diagnostic validation. In 77 healthy subjects and 58 patients with GH deficiency confirmed by insulin tolerance test, 100 mcg of GHRP-2 intravenously produced a GH peak within 60 minutes in every participant, and the test separated deficient from healthy subjects well enough to serve as an ITT alternative (Chihara 2007). A Japanese comparison in 71 pre-operative pituitary-tumour patients found a median peak GH of 28.9 mcg/L with GHRP-2 against 9.4 mcg/L with the ITT and 4.4 mcg/L with arginine (Kinoshita 2013). This is the use Japan licensed.

Thirty days of continuous exposure. The most informative chronic study infused GHRP-2 at 1 mcg/kg/h subcutaneously for 30 days in 17 healthy older adults. Pulsatile GH secretion rose more than threefold on day 1 and about 1.8-fold on days 14 and 30. IGF-1 reached a stable plateau and stayed there, and IGFBP-3 and IGFBP-5 also rose (Bowers 2004). So the axis partially adapts, but IGF-1 elevation persists for at least a month. The same study found acute GHRP-2 and GHRH synergy was threefold greater in young than in older volunteers.

Appetite. Seven lean healthy men infused with GHRP-2 at 1 mcg/kg/h for 270 minutes ate 35.9% more at an ad libitum buffet than on saline, with every subject increasing intake (Laferrère 2005). A follow-up in 10 lean and 9 obese subjects found the effect dose-dependent: 10.2% more food at 0.1 mcg/kg/h and 33.5% more at 1 mcg/kg/h, with obesity making no difference to the response (Laferrère 2006).

Clinical settings. Fourteen patients in protracted critical illness received GHRP-2 plus TRH at 1 + 1 mcg/kg/h for five days, which reactivated pulsatile GH and TSH release and improved markers of anabolism (Van den Berghe 1999). In children of short stature, intranasal GHRP-2 at 5-20 mcg/kg produced GH responses above 10 mcg/L, and a small treatment study gave it two to three times daily for several months (Pihoker 1995, Pihoker 1997). One published case report describes intranasal GHRP-2 before every meal for a year in a severely emaciated patient with 20-year anorexia nervosa, with a 6.7 kg weight gain and improved hypoglycaemia (Haruta 2015). One patient is a hypothesis, not a result.

What is missing

No randomised trial has tested GHRP-2 against placebo for fat mass, lean mass, strength, sleep quality, recovery from injury or any patient-reported outcome. The most recent narrative review of this compound class makes the same point and places GHRP-2 well below trial-grade evidence on its own evidence ladder (Dominikowski 2026).

Dosing

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Titration as it is actually done. Protocols start at one injection of 100 mcg daily for the first week to see how hunger, fluid retention and sleep respond, then add a second and third daily injection. The “saturation dose” argument that circulates in protocol write-ups, that around 100 mcg per injection already saturates the GH response and more mostly adds prolactin and cortisol, matches the dose-response shape measured for hexarelin at the same receptor (Massoud 1996), but has never been tested formally for subcutaneous GHRP-2.

On and off cycle. Typical blocks are 8-12 weeks with four weeks off, sometimes rotating with ipamorelin. The pharmacological reason to cycle is real: GH responsiveness falls with continuous exposure, to roughly half the day-1 effect by day 14 in the 30-day infusion study (Bowers 2004).

Reconstitution, storage and injection technique are covered in the peptide injection guide. Cycle structure across compounds is in peptide cycling protocols.

What people report: what works and what doesn’t

The sources here are the aggregated community data sets (Peptide Protocol Wiki, 110 reports; Peptide DB), the protocol and adverse-effect patterns catalogued in the peer-reviewed review of this class (Dominikowski 2026), and published case material. These are patterns, not proof.

Reported to work

• Hunger, within 20-40 minutes of an injection. The most consistent single report, and the one with direct trial support behind it. Moderate with GHRP-2, far stronger with GHRP-6.
• Deeper sleep in the first weeks when the dose is taken before bed, described widely and consistent with GH physiology, but never measured against placebo with polysomnography for this peptide.
• Fluid retention and a fuller look within 1-2 weeks at 200-300 mcg daily, usually read as a GH effect rather than new muscle.
• A measurable IGF-1 rise in people who test. This is the one claim the trial data support directly.

Mixed or unclear

• Recovery and joint comfort. Frequently described, and just as often attributed to the GHRH analogue in the stack or to a training change.
• Fat loss. Reports split sharply, and the appetite effect works against it. No trial has measured fat mass on GHRP-2.
• Whether dose matters above roughly 100-150 mcg per injection. Protocol writers argue both sides and the human subcutaneous dose-response data do not exist to settle it.

Reported not to work, or disappointing

• Muscle gain on GHRP-2 alone. The most common disappointment, and what the pharmacology predicts: pulsatile GH elevation inside the physiological range is not an anabolic steroid.
• Effects fading after several weeks of uninterrupted use, which matches the partial desensitisation seen in the infusion study.
• Side effects people stop for: hunger strong enough to derail a diet, morning puffiness, tingling in the hands, and in a minority lethargy or low mood that gets attributed to prolactin or cortisol shifts. Mildly raised prolactin or cortisol in a user of this class is a recognised pattern rather than a sign of pituitary disease (Dominikowski 2026).

What a properly designed trial would need to show: a randomised, placebo-controlled study of at least 12 weeks in adults with low IGF-1, reporting visceral fat by imaging, lean mass, strength and glucose tolerance, with prolactin, cortisol and IGF-1 tracked throughout.

Safety and side effects

Observed in human studies. Acute studies report facial flushing, transient drowsiness, sweating and a metallic taste. The 30-day infusion was reported as safe and well tolerated in older adults. Prolactin, ACTH and cortisol rise modestly at GH-releasing doses (Arvat 1997).

Predictable from GH physiology. Fluid retention, carpal-tunnel-type paraesthesia, arthralgia and reduced insulin sensitivity. GH is a counter-regulatory hormone, so anyone with prediabetes, diabetes or metabolic syndrome needs glucose and HbA1c watched. FDA specifically cites effects on cortisol and blood glucose as a concern for this class.

The IGF-1 question. Sustained IGF-1 elevation is the point of the intervention and also its main open risk. Higher circulating IGF-1 associates with increased risk of prostate and premenopausal breast cancer in epidemiological data (Renehan 2004). Nobody has shown that months of pulsatile GHRP-2 use changes cancer risk, and nobody has shown that it does not. Active malignancy is a contraindication in my reading, as it is on the labels of approved GH-axis drugs.

Adverse events on FDA’s record. In the safety summary attached to its compounding lists, FDA cites reports of serious adverse events with GHRP-2, including a death in critically ill study subjects, infection and pancreatitis, while stating that causality has not been established. That is a weak signal from a very sick population, but it is on the record and belongs in the conversation.

Not studied at all: use beyond 30 days continuously or 12 weeks intermittently, use in pregnancy or lactation, use in children outside the small short-stature studies, and interactions with insulin, GLP-1 agonists or glucocorticoids (glucocorticoids blunt GH release).

Product quality. Of 1,190 doping products seized at the Swiss border, 12% were labelled as peptide hormones or growth factors, and poor pharmaceutical quality was a recurring finding (Weber 2017). Analytical work on confiscated vials has found wrong contents, bacterial fusion-protein tags and oxidised degradation products. See peptide sourcing.

Legal and regulatory status

United States. No approved GHRP-2 product. On FDA’s 503A bulk drug substance list (updated 14 May 2026) GHRP-2 sits in category 3, nominated without adequate supporting information, so it is not covered by the interim enforcement policy that applies to category 1 substances. Under the separate 503B outsourcing-facility policy it is in category 2, substances that raise significant safety risks, where FDA cites immunogenicity risk from aggregation, peptide-related impurities and the adverse-event reports above. What the category system does and does not mean is covered in the FDA 2026 compounding update.

Japan. Pralmorelin hydrochloride is licensed as a diagnostic agent for growth hormone deficiency, given as a single injection (Drugs R D 2004). This is the only approval GHRP-2 holds anywhere, and it is for a test rather than a treatment.

European Union and Germany. No EMA or BfArM authorisation, so a product sold as GHRP-2 in the EU is an unlicensed substance. Germany’s Anti-Doping Act (AntiDopG) names GHRP-2, GHRP-2-Gly, GHRP-6, GHRP-6-Gly and hexarelin in its annex as growth hormone releasing peptides, and § 2(3) makes it an offence to acquire, possess or import more than a “non-small quantity” of a listed substance for the purpose of doping in sport. The implementing regulation (DmMV, in force since 16 March 2023) sets that threshold at 1.5 mg for the GHRP group, which is less than a single 5 mg vial. The offence turns on the doping purpose, but the threshold is low enough that anyone in Germany should know where it sits.

Sport. Prohibited at all times under section S2 of the WADA list, which covers peptide hormones, growth factors, related substances and mimetics. The prohibition works by class, so every GHRP is covered whether or not it is named. Detection is routine: laboratories identify GHRP-2 and its metabolites in urine and, since 2021, in dried blood spots, which extends the detection window (Reverter-Branchat 2021). More in peptides and anti-doping rules.

How GHRP-2 fits next to the alternatives

If the goal is a clean GH pulse with the fewest hormonal side effects, ipamorelin is the better-behaved molecule. If the goal is visceral fat reduction with trial evidence behind it, that is tesamorelin, an approved medicine in its indication. GHRP-2’s distinctive position is the combination of a big reproducible pulse, a licensed diagnostic use that shows the molecule behaves predictably in humans, and the appetite effect, which is either the point or the problem depending on the person.

What I would want before treating this as more than an interesting pharmacological tool is the 12-week randomised trial that nobody has run.

Related Articles

• CJC-1295/Ipamorelin: Growth Hormone Secretagogues — the GHRP plus GHRH combination logic in detail.
• Ipamorelin: A Physician’s Guide — the selective alternative at the same receptor.
• Peptides for Muscle Growth: What the Evidence Actually Supports — where GH secretagogues sit against the rest.
• Peptide Therapy for Athletes: What’s Banned Under WADA Rules in 2026 — class-based prohibition and detection windows.
• FDA 2026 Peptide Compounding Update — what the category lists actually say.